(Q33355350)

26 July 2017

Establishment and characterization of a novel ovarian clear cell adenocarcinoma cell line, TU-OC-1, with a mutation in the PIK3CA gene (English)

1 reference

clear cell adenocarcinoma

26 July 2017

0 references

1 reference

1 reference

ovarian clear cell adenocarcinoma

inferred from title

1 reference

13

Junzo Kigawa

1 reference

26 July 2017

1

Hiroaki Itamochi

1 reference

26 July 2017

5

Tetsuro Oishi

1 reference

26 July 2017

7

Shinya Sato

1 reference

26 July 2017

6

Muneaki Shimada

1 reference

26 July 2017

14

Tasuku Harada

1 reference

26 July 2017

12

Naoki Terakawa

1 reference

26 July 2017

2

Misaki Kato

1 reference

26 July 2017

3

Mayumi Nishimura

1 reference

26 July 2017

11

Akiko Kudoh

1 reference

26 July 2017

4

Nao Oumi

1 reference

26 July 2017

Jun Naniwa

8

1 reference

26 July 2017

Seiya Sato

series ordinal

9

1 reference

26 July 2017

Michiko Nonaka

series ordinal

10

1 reference

26 July 2017

21 February 2013

1 reference

26 July 2017

1 reference

26 July 2017

26

1 reference

26 July 2017

121-127

1 reference

26 July 2017

3

1 reference

describes a project that uses

26 July 2017

0 references

0 references

0 references

0 references

https://scigraph.springernature.com/pub.10.1007/s13577-013-0062-y

0 references

cites work

Mechanisms of chemoresistance and poor prognosis in ovarian clear cell carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS13577-013-0062-Y

Clear cell carcinoma of the ovary: a retrospective multicentre experience of 254 patients with complete surgical staging.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13577-013-0062-Y

The PI3K-PDK1 connection: more than just a road to PKB

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13577-013-0062-Y

The phosphatidylinositol 3-Kinase AKT pathway in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13577-013-0062-Y

Inhibition of the PI3K pathway: hope we can believe in?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13577-013-0062-Y

Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13577-013-0062-Y

PIK3CA mutation is an early event in the development of endometriosis-associated ovarian clear cell adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13577-013-0062-Y

Mutations of PIK3CA in gastric adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13577-013-0062-Y

Mutant PIK3CA promotes cell growth and invasion of human cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13577-013-0062-Y

Low proliferation activity may be associated with chemoresistance in clear cell carcinoma of the ovary.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13577-013-0062-Y

Mechanisms of cisplatin resistance in clear cell carcinoma of the ovary.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13577-013-0062-Y

Novel mechanism of reduced proliferation in ovarian clear cell carcinoma cells: cytoplasmic sequestration of CDK2 by p27.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13577-013-0062-Y

Ovarian cancer: strategies for overcoming resistance to chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13577-013-0062-Y

Targeted therapies in epithelial ovarian cancer: Molecular mechanisms of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13577-013-0062-Y

High frequency of mutations of the PIK3CA gene in human cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13577-013-0062-Y

Oncogenic PI3K deregulates transcription and translation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13577-013-0062-Y

PI3K pathway inhibitors approach junction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13577-013-0062-Y

ARID1A mutations in endometriosis-associated ovarian carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13577-013-0062-Y

Subtype-specific mutation of PPP2R1A in endometrial and ovarian carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13577-013-0062-Y

Somatic mutations of PPP2R1A in ovarian and uterine carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13577-013-0062-Y

The PI3K pathway as drug target in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13577-013-0062-Y

Differential drug sensitivity conferred by growth status detected in a mixed population of cycling and noncycling cells.

21 January 2018

1 reference

12 December 2020

Mesonephroid tumors of the ovary. Clinical and histopathologic studies.

1 reference

12 December 2020

Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy

1 reference

12 December 2020

Confluence-dependent resistance in human colon cancer cells: role of reduced drug accumulation and low intrinsic chemosensitivity of resting cells

1 reference

12 December 2020

World Health Organization classification and nomenclature of ovarian cancer

1 reference

12 December 2020

10.1007/S13577-013-0062-Y

Identifiers

DOI

1 reference

Dimensions Publication ID

26 July 2017

0 references

1 reference